Contract manufacturer designing and producing precision components for medical devices like ventilators and auto-injectors.
Contract manufacturer designing and producing precision components for medical devices like ventilators and auto-injectors.
Works as an outsourced design-and-manufacturing partner for device makers, paid per unit shipped once a customer has approved the part. Revenue depends on a limited number of large customers' programmes, and moulding and assembly skill is what it sells.
In one line: A Chinese medical-device CDMO, like a smaller Flex Health Solutions.
Moat: narrow (process know-how, customer qualification). Design-to-manufacturing qualification with device OEMs is costly to switch mid-program.
Headquarters: Shenzhen, China · Founded: 2010 · Employees: 3,101
Size Mehow Innovative (301363.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.72B, the 1338th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥14.75 on 18 Nov 2026.
Performance Over six months the shares fell 35.8%, against +3.5% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue grew 9.9% over the last twelve months (peer median +10.6%); the operating margin is 20.7% (peer median 12.7%).
Valuation It trades at 34.2× forward earnings against a peer median of 25.1× (8th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 6.4 points above its cost of capital (8.9% WACC).
Next results Next results expected around 22 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.79B | CN¥1.61B | CN¥1.58B | CN¥1.33B | CN¥1.41B |
| Revenue growth | — | +2% | +19% | -5% | — |
| Gross profit | CN¥797M | CN¥606M | CN¥631M | CN¥518M | CN¥580M |
| EBITDA | n/a | CN¥397M | CN¥441M | CN¥361M | CN¥469M |
| Net income | CN¥309M | CN¥283M | CN¥364M | CN¥313M | CN¥402M |
| Free cash flow | CN¥169M | -CN¥103M | CN¥95.2M | CN¥107M | CN¥180M |
| Capital expenditure | CN¥234M | CN¥462M | CN¥363M | CN¥259M | CN¥201M |
| Total debt | CN¥118M | CN¥111M | CN¥19.0M | CN¥45.2M | CN¥32.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Mehow Innovative 301363.SZ | $1.72B | -36% | +10% | 21% | 34.2× | 16.4% |
| Flex FLEX | $27.7B | -43% | +18% | 6% | 11.7× | 17.6% |
| Jabil JBL | $25.5B | -28% | +21% | 5% | 14.0× | 9.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301363.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.9% | -4.4% | 7th lowest of 21 |
| 6-month return | -35.8% | +3.5% | 3rd lowest of 20 |
| Distance from 52-week high | -52.3% | -23.2% | 4th lowest of 21 |
| Revenue growth (TTM) | +9.9% | +10.6% | 11th highest of 21 |
| Operating margin | 20.7% | 12.7% | 4th highest of 21 |
| Forward P/E | 34.2× | 25.1× | 8th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 16.4% | 11.2% | 6th most demanding of 14 |
| Growth delivered (Del g) | +12.9% | +12.7% | 7th highest of 14 |
| Hurdle (Req g minus delivered) | +3.5 pp | -0.6 pp | 5th most demanding of 14 |
| ROIC minus cost of capital | +6.4 pp | -0.6 pp | 6th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Mehow Innovative 301363.SZ | China | $1.72B | -36% | +10% | 21% | 34.2× | 16.4% | +12.9% |
| Embla Medical hf EMBLA.CO | Denmark | $1.72B | +1% | +6% | 14% | 17.2× | -1.9% | +8.3% |
| LeMaitre Vascular LMAT | United States | $1.73B | -25% | +12% | 28% | 24.5× | 2.9% | +14.0% |
| DENTSPLY SIRONA XRAY | United States | $1.69B | -13% | -1% | 5% | 6.8× | 11.2% | +1.9% |
| Kestra Medical Technologies KMTS | United States | $1.69B | +36% | +61% | -134% | n/a | n/a | n/a |
| Inspire Medical Systems INSP | United States | $1.68B | +32% | 0% | 2% | 41.3× | 28.7% | +51.2% |
| NIPRO 8086.T | Japan | $1.68B | -11% | +5% | 5% | 15.8× | n/a | n/a |
| ChemoMetec A/S CHEMM.CO | Denmark | $1.77B | +107% | +3% | 49% | 46.7× | 19.4% | +12.7% |
| Nakanishi 7716.T | Japan | $1.78B | +7% | +17% | 21% | 19.0× | 4.8% | +19.7% |
| Poly Medicure POLYMED.NS | India | $1.79B | +14% | +25% | 16% | 39.9× | n/a | n/a |
| Butterfly Network BFLY | United States | $1.63B | +38% | +39% | -36% | n/a | n/a | n/a |
| Angelalign Technology 6699.HK | Hong Kong | $1.62B | -8% | +84% | 9% | 52.5× | 16.7% | +25.8% |
| Shandong Weigao Group Medical Polymer 1066.HK | Hong Kong | $1.82B | -8% | +7% | 14% | 8.2× | -12.6% | +2.1% |
| Fukuda Denshi 6960.T | Japan | $1.84B | +4% | 0% | 19% | 15.4× | -1.6% | -1.0% |
| Rigaku 268A.T | Japan | $1.85B | -54% | +9% | 16% | 23.1× | 18.3% | +14.5% |
| Molbio Diagnostics MOLBIO.NS | India | $1.85B | n/a | +35% | 17% | n/a | n/a | n/a |
| Cofoe Medical Technology 301087.SZ | China | $1.60B | -6% | +33% | 10% | 25.1× | 11.2% | +7.4% |
| SKAN SKAN.SW | Switzerland | $1.85B | +40% | +9% | 11% | 49.5× | 13.8% | +11.7% |
| Medartis MED.SW | Switzerland | $1.86B | +47% | +30% | 2% | 72.8× | n/a | n/a |
| Wuxi Unicomp Technology 688531.SS | China | $1.58B | -49% | +53% | 12% | 35.8× | n/a | n/a |
| Vitrolife VITR.ST | Sweden | $1.57B | +13% | -2% | 19% | 27.0× | 22.2% | +22.5% |